Apply to trial NCT05755087

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Procedure

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening